Neulasta (pegfilgrastim) is a prescription drug used to prevent infection from certain cancer therapy and to treat radiation sickness. Neulasta’s cost may depend on factors such as your dosage and the ...

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe ...

This is the company's third biosimilar Biologics License Application in the United States. After a lot of skirmish, Sandoz was finally able to launch the first-ever biosimilar product in the United ...

Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...

Nearly two years after taking tremendous heat for the rising cost of EpiPens, pharmaceutical giant Mylan is making strides in the fast-growing market for biosimilars. Biosimilars are potentially ...

The FDA dealt Novartis’ Sandoz unit a blow last summer when it issued a complete response letter for the company’s biosimilar version of Amgen’s blockbuster drug Neulasta (pegfilgrastin). The Swiss ...

Before you start treatment with Neulasta, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

Amgen will lose its patent for Neulasta in 2015, opening up the $4 billion in sales revenue to a rival generic. As the second-highest-earning drug for Amgen, will the company be able to make up the ...

Coherus BioSciences plans to price its biosimilar of Amgen’s Neulasta, an infection-fighting treatment, at $4,175 per unit, according to Reuters. This is a 33 percent discount off the price of the ...

Mylan N.V.MYL and partner Biocon Ltd. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ...